Table 1.
Demographic, clinical and laboratory characteristics of all groups
| Variables | Group 1, (n = 87) | Group 2, (n = 93) | Group 3, (n = 92) | P |
|---|---|---|---|---|
| Demographic features | ||||
| Age.years | 58.7 ± 17.7*a.b.c | 63.8 ± 16.0 | 66.13 ± 16.00 | 0.01 |
| Gender (Male/Female | 45/42 | 54/39 | 54/38 | 0.58 |
| Malignancy. n (%) | 14 (16.1) | 24 (25.8) | 18 (19.6) | 0.26 |
| CAD n (%) | 9 (10.3) | 16 (17.4) | 23 (25) | 0.04 |
| Hypertension. n (%) | 26 (30.2) | 30 (32.3) | 40 (43.5) | 0.13 |
| DiabetesMellitus. n (%) | 12 (13.8) | 16 (17.2) | 23 (25) | 0.14 |
| HemodynamicParameters | ||||
| SystolicBp (mmHg) | 112.1 ± 18.5 | 113.0 ± 21.7 | 109.6 ± 23.7 | 0.56 |
| DiastolicBp (mmHg) | 70.4 ± 10.8 | 69.9 ± 12.2 | 70.8 ± 14,0 | 0.96 |
| Heart Rate (bpm) | 87.5 ± 21 | 107.4 ± 115 | 118.2 ± 145,2 | 0.20 |
| O2 saturation (%) | 87.3 ± 17.3 | 87.1 ± 8.5 | 86.8 ± 15.6 | 0.98 |
| SHOCK index | 0.8 ± 0.2 | 1,0 ± 0.1 | 1.1 ± 1.3 | 0.11 |
| Laboratory Findings | ||||
| WBC | 9.5 ± 3.6 | 10.7 ± 4.7 | 12.77 ± 6.3 | 0.0001 |
| Haemoglobin (g/dL) | 14.1 ± 15.5 | 11.7 ± 2.3 | 12.5 ± 8.9 | 0.14 |
| TroponinT mg/dL, median (IQR) | 0.11(0.17)a | 0.12(0.24) | 0.23(0.48) | 0.03 |
| Clinical scores | ||||
| Genevascore | 8,8 + 12,5 | 7,8 + 3,5 | 7,3 + 3,4 | 0,44 |
| Wellsscore | 5,5 + 2,0 | 5,4 + 2,0 | 5,2 + 1,6 | 0,69 |
| Echocardiographic measurements | ||||
| RV dilatation (%) | 27 (50.9) | 30 (68.2) | 38 (74.5) | 0.04 |
| EF | 59.0 ± 7.5 | 57.7 ± 7.5 | 58.6 ± 6.1 | 0.64 |
| PAB | 52.6 ± 21.4 | 57.1 ± 16.3 | 54.9 ± 18.3 | 0.45 |
| RVLV ratio | 1,03 ± 0,16 | 1,16 ± 0,20 | 1,28 ± 0,23 | 0.001 |
| clinical outcome for 30 days | ||||
| Death | 2 (2.3) | 10 (10.8) | 24 (26.1) | 0.001 |
| Combine endpoint | 3 (3,5)*a | 14 (15,1) | 25 (27,5) | 0,001 |
*abc means that statitically significant differece between subgroups as a: group1 vs. 2, b: group 1 vs 3, c: group 2 vs. 3